Cenobamate in brain tumor‐related epilepsy: A multicenter real‐world experience

OBJECTIVE: Cenobamate (CNB) is a novel antiseizure medication with a dual mechanism of action that has demonstrated high efficacy in drug-resistant focal epilepsy; however, evidence in brain tumor-related epilepsy (BTRE) remains limited. The study aimed to evaluate the effectiveness, safety, and tolerability of CNB as add-on therapy in a multicenter cohort of patients with BTRE. METHODS: We conducted a multicenter, retrospective observational study across tertiary epilepsy centers in the Lazio region, Italy. Adult patients with drug-resistant BTRE treated with CNB as adjunctive therapy were included. Seizure frequency was assessed at baseline and during follow-up. Primary outcomes were changes in monthly seizure frequency and responder rates. Effectiveness was analyzed in both the overall population and in a homogeneous cohort of patients with 6-month follow-up. RESULTS: Twenty patients (10 females, median age 48 years) were included. Tumor histology included meningioma (n = 7, 35%), astrocytoma (n = 4, 20%), glioblastoma (n = 3, 15%), ganglioglioma (n = 3, 15%), oligodendroglioma (n = 2, 10%), and dysembryoplastic neuroepithelial tumor (n = 1, 5%). In the overall analysis population (n = 20), after a median 12-month follow-up, median seizure frequency significantly decreased from 6 to 1 per month (p < 0.001), with a median reduction of 85.8% (IQR 51.4-96.7). Responder rates were 80% (≥50% seizure reduction), 60% (≥75%), and 20% achieved seizure freedom. Adverse events occurred in 12 patients (60%), including sedation (n = 8, 40%), postural instability (n = 3, 15%), diarrhea, and mild cutaneous rash (n = 1, 5% each). CNB was discontinued in one patient (5%). SIGNIFICANCE: In this multicenter real-world cohort of patients with drug-resistant BTRE and heterogeneous tumor histology, CNB was associated with a reduction in seizure frequency and was well tolerated. PLAIN LANGUAGE SUMMARY: Seizures caused by brain tumors can be difficult to control. We reviewed records from 20 adults who received cenobamate alongside their existing seizure medicines. At their last follow-up, 16 had at least half as many seizures, and four were seizure-free. Twelve patients experienced side effects, most commonly sleepiness; one stopped cenobamate because of a rash. These findings suggest that cenobamate may help some people with brain tumor-related epilepsy. However, the study was small, had no comparison group, and included patients with different tumors and follow-up durations. Larger studies are needed.

Authors

Institutions

Publication Details

Journal
Epilepsia Open
Published
2026-11-16
DOI
https://doi.org/10.1002/epi4.70365
Primary Topic
Epilepsy research and treatment
Type
article
Field-Weighted Citation Impact
0.00
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
NOV
article

Cenobamate in brain tumor‐related epilepsy: A multicenter real‐world experience

Patrizia Pulitano, Marta Piccioli, Mariana Fernandes, Marina Romozzi et al.
6 links
Epilepsia Open
Epilepsy research and treatment
article

Cenobamate in brain tumor‐related epilepsy: A multicenter real‐world experience

Patrizia Pulitano, Marta Piccioli, Mariana Fernandes, Marina Romozzi, Paolo Tisei, Catello Vollono, Paolo Calabresi, Claudio Liguori, Giulia Lippa, Maria Antonietta Bassetti, Matteo Antonucci, Marta Maschio, Mario Tombini, Giovanni Assenza, Adolfo Mazzeo
article en

Abstract

OBJECTIVE: Cenobamate (CNB) is a novel antiseizure medication with a dual mechanism of action that has demonstrated high efficacy in drug-resistant focal epilepsy; however, evidence in brain tumor-related epilepsy (BTRE) remains limited. The study aimed to evaluate the effectiveness, safety, and tolerability of CNB as add-on therapy in a multicenter cohort of patients with BTRE. METHODS: We conducted a multicenter, retrospective observational study across tertiary epilepsy centers in the Lazio region, Italy. Adult patients with drug-resistant BTRE treated with CNB as adjunctive therapy were included. Seizure frequency was assessed at baseline and during follow-up. Primary outcomes were changes in monthly seizure frequency and responder rates. Effectiveness was analyzed in both the overall population and in a homogeneous cohort of patients with 6-month follow-up. RESULTS: Twenty patients (10 females, median age 48 years) were included. Tumor histology included meningioma (n = 7, 35%), astrocytoma (n = 4, 20%), glioblastoma (n = 3, 15%), ganglioglioma (n = 3, 15%), oligodendroglioma (n = 2, 10%), and dysembryoplastic neuroepithelial tumor (n = 1, 5%). In the overall analysis population (n = 20), after a median 12-month follow-up, median seizure frequency significantly decreased from 6 to 1 per month (p < 0.001), with a median reduction of 85.8% (IQR 51.4-96.7). Responder rates were 80% (≥50% seizure reduction), 60% (≥75%), and 20% achieved seizure freedom. Adverse events occurred in 12 patients (60%), including sedation (n = 8, 40%), postural instability (n = 3, 15%), diarrhea, and mild cutaneous rash (n = 1, 5% each). CNB was discontinued in one patient (5%). SIGNIFICANCE: In this multicenter real-world cohort of patients with drug-resistant BTRE and heterogeneous tumor histology, CNB was associated with a reduction in seizure frequency and was well tolerated. PLAIN LANGUAGE SUMMARY: Seizures caused by brain tumors can be difficult to control. We reviewed records from 20 adults who received cenobamate alongside their existing seizure medicines. At their last follow-up, 16 had at least half as many seizures, and four were seizure-free. Twelve patients experienced side effects, most commonly sleepiness; one stopped cenobamate because of a rash. These findings suggest that cenobamate may help some people with brain tumor-related epilepsy. However, the study was small, had no comparison group, and included patients with different tumors and follow-up durations. Larger studies are needed.

Epilepsia Open
Università Cattolica del Sacro Cuore (IT), University of Rome Tor Vergata (IT), Università Campus Bio-Medico (IT), Azienda Ospedaliera San Giovanni Addolorata (IT), Agostino Gemelli University Polyclinic (IT), ASL Roma (IT), Ospedale San Filippo Neri (IT), Policlinico Tor Vergata (IT), Campus Bio Medico University Hospital (IT), Istituti di Ricovero e Cura a Carattere Scientifico (IT), Sapienza University of Rome (IT)
Good health and well-being
Epilepsy research and treatment
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.

Laika access coming soon